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A method for suppression of virus reproduction in cells using fatty acylated antiviral antibodies, which in contrast to 
non-modified antibodies are capable of intracellular penetration, has been suggested. The addition of stearoylated antivi- 
ral antibodies to influenza A/Chili virus-infected cells causes a lOO-fold suppression of virus reproduction. Non-modified 
antibodies do not produce any effect on virus reproduction. 
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1. INTRODUCTION 
Modern biotechnology uses highly effective 
means for the production of antibodies against an- 
tigen determinants of different viruses. This fact 
ensures the rapid progress in the development of 
methods for the diagnoses and investigation of 
viral diseases [1,2]. This raises the question: why 
are antiviral antibodies not used practically [2] for 
the therapy of such diseases and, in particular, for 
the suppression of virus reproduction. 
It is known that antibodies against virus can pre- 
vent the infection of cells by this virus [3]. How- 
ever, the same antibodies do not affect the develop- 
ment of infection in already infected cells, since 
they cannot penetrate into them and block intra- 
cellular reproduction of the virus [4]. 
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An effective method for imparting transmem- 
brane properties to water-soluble proteins has been 
developed recently [5-71. For this purpose, a lipid 
‘anchor’ (fatty acid residue) is covalently attached 
to the protein molecule. As a result, hydrophob- 
ized proteins retain their functional activity, ac- 
quiring an ability for translocation across lipid 
membranes and penetration into infected cells. 
In the present work we have used influenza 
A/Chili/l/83(HlNl) virus to study possibilities of 
suppression of virus reproduction by antiviral anti- 
bodies, artificially hydrophobized with stearic acid 
residues. 
2. MATERIALS AND METHODS 
2.1. Cells 
MDCK cells were kindly presented by the Laboratory of Cell 
Cultures (Institute of Virology, USSR Academy of Medical 
Sciences). Cells were grown as a monolayer stationary culture in 
199 medium, containing 10 mM Hepes, 0.075% sodium bicar- 
bonate, 10% fetal calf serum and 200 rg/ml gentamycin. 
2.2. Antibodies and their modification 
To obtain polyclonal antibodies against influenza A/Chili 
virus, mice were immunized according to a standard technique 
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[8]. Modification of antibodies by stearoyl chloride was carried 
out in the system of reversed micelles of Aerosol OT in octane 
by the method detailed in [5,9]. 1.5 ml of 50 mM solution of an- 
tibodies in 0.1 M borate buffer, pH 9.5, were added to 10 ml of 
0.3 M Aerosol OT solution (Merck) in octane. The system was 
intensively shaked at 20°C for l-2 min to achieve optical densi- 
ty, and then 1.5 ml of 0.25 mM stearoyl chloride solution in oc- 
tane were added to it. Stearoyl chloride was obtained by treating 
stearic acid (Sigma) with thionyl chloride and purified by 
distillation in vacuum. After 2 h the protein was precipitated 
with 30 ml of cold (0°C) acetone. The precipitate formed was 
then removed by centrifugation and thoroughly washed five 
times with 30 ml of cold (4°C) acetone. The residual acetone 
was removed using a rotor evaporator. The modified antibodies 
were purified by gel filtration on Biogel P2. 
The modification degree was determined as described 191 us- 
ing [3H]stearoyl chloride for modification. 
The affinity of antibodies before and after modification was 
determined by indirect immunoassay using peroxidase-labelled 
antispecies antibodies. 
2.3. Virus reproduction 
A monolayer of permissive MDCK cells was infected with in- 
fluenza A/Chili virus at 10 PFU per cell. 3.5 h post-infection 
the antibodies were added to the cell culture at a concentration 
equal to their hemagglutination titre (about lOag/ml). 8.5 h 
post-infection the cells were thoroughly washed twice with 
2 vols of the medium to remove the antibodies, then incubated 
for 1 h with 2 vols of the medium, and washed once again with 
5 vols of the same medium. 
The cells were incubated for 24 h with fresh (devoid of anti- 
bodies) culture medium. Then the culture medium was 
separated and lightened by double centrifugation at 6000 x g for 
15 min. The infection (1 g PFU/ml) and hemagglutination 
(HAWml) titres were assayed in the supernatant as detailed in 
1101. 
3. RESULTS AND DISCUSSION 
To introduce stearic acid residues into antibody 
molecules, the latter were modified with stearoyl 
chloride using the system of surfactant reversed 
micelles in an organic solvent (Aerosol OT in oc- 
tane) [5,9]. The modified antibodies contained two 
residues of stearic acid per protein globule and re- 
tained 80% activity in comparison with initial 
(non-modified) antibodies. 
The data presented in fig. 1 indicate that incuba- 
tion of influenza A/Chili virus-infected MDCK 
cells with non-modified polyclonal antibodies 
against this virus for several hours does not prac- 
tically affect the development of infection. Under 
these conditions hydrophobized antiviral anti- 
bodies decrease the virus reproduction almost by 2 
orders. 
Special experiments have proved that hydro- 
Fig.1. Reproduction of influenza A/Chili/l/83(H1Nl) virus in 
permissive MDCK cells in the presence of: (1) stearoylated nor- 
mal mouse I@; (2) non-modifiedi~and (3) stearoylated poly- 
clonal antibodies against influenza AiChili virus. (a) Infection 
titre. (b) Hemagglutination titre. The dotted lines show the 
values of infection and hemagglutination titres in the control ex- 
periment (in the absence of antibodies). 
phobized antibodies do not produce a toxic effect 
on infected cells, i.e., a decrease in virus reproduc- 
tion observed is not connected with cell destruction 
in the presence of antibodies. 
It should be noted that after acquiring an ability 
to suppress virus reproduction in cells, hydro- 
phobized antibodies retain their specific properties: 
the addition of stearoylated normal IgG, which are 
not able to interact specifically with influenza virus 
antigenic determinants, does not affect virus 
reproduction in infected cells (fig. 1). 
The data obtained do not fully account for the 
mechanism of the discovered phenomenon. How- 
ever, it is highly probable that hydrophobized anti- 
bodies penetrate into infected cells and block the 
assemblage of virus particles and/or the synthesis 
of virus components. Stearoylated monoclonal an- 
tibodies against the NP-protein (the internal an- 
tigen of the influenza virus, which is accessible to 
antibodies only inside the cell [l 11) possess a con- 
siderable antiviral activity (data not presented). 
These findings certainly support the above made 
assumption. 
In any case, we believe that the method of sup- 
pression of virus reproduction by artificially 
hydrophobized antiviral antibodies can be applied 
for the therapy of different viral infections, and, in 
particular, those that have no safe methods of 
treatment yet. In this connection the key problem is 
whether artificially hydrophobized antiviral anti- 
bodies can penetrate into infected cells and ac- 
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cumulate there suppressing the development of in- 
fection. In other words, can antibodies be directly 
transported to antigens, separated from them by 
cellular membranes? Recently, a principle of im- 
parting transmembrane properties to proteins [5] 
has been successfully applied for the directed 
transport of antibodies across the hemato- 
encephalic barrier in the brain [12]. These findings 
certainly give ground to a positive answer to this 
question. 
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